Androgen deprivation therapy (ADT) is a standard therapy for some localized and almost all metastatic prostate cancer (PCa) patients. Although several clinical cohort studies have identified an impact of ADT on the cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer’s disease (AD).